PIKHER2:buparlisib联合拉帕替尼治疗曲妥珠单抗耐药HER2阳性晚期乳腺癌的IB期研究
PIKHER2是一项IB期研究,旨在确定buparlisib联合拉帕替尼在HER2阳性、曲妥珠单抗耐药的晚期乳腺癌中的最大耐受剂量(MTD)和II期推荐剂量(RP2D)。共24例患者接受五个剂量水平治疗,MTD为buparlisib 80 mg/d联合拉帕替尼1250 mg/d,但因毒性和早期停药,RP2D选择buparlisib 80 mg联合拉帕替尼1000 mg/d。疾病控制率为79%[95%CI 57-92%],临床获益率为29%[95%CI 12-51%]。
要点
- MTD为buparlisib 80 mg/d联合拉帕替尼1250 mg/d
- RP2D为buparlisib 80 mg联合拉帕替尼1000 mg/d
- 疾病控制率79%[95%CI 57-92%],临床获益率29%[95%CI 12-51%]
核心结论
- buparlisib联合拉帕替尼在HER2阳性、曲妥珠单抗耐药的晚期乳腺癌中可行,并在重度经治人群中观察到初步抗肿瘤活性证据。
研究设计与样本
- PIKHER2是一项IB期研究,主要目的是确定buparlisib联合拉帕替尼在HER2阳性、曲妥珠单抗耐药的晚期乳腺癌中的MTD和RP2D。
- 口服buparlisib(40、60或80 mg)和拉帕替尼(750、1000或1250 mg)每日给药,采用改良连续 reassessment 方法(自适应贝叶斯模型)指导两药剂量递增。
- 共24例患者接受五个剂量水平治疗;次要终点包括抗肿瘤活性和药代动力学(PK)评估。
主要发现
- 剂量限制性毒性包括转氨酶升高、呕吐、口腔炎、高血糖和腹泻。
- MTD为buparlisib 80 mg/d联合拉帕替尼1250 mg/d,但毒性和第1周期后早期治疗停药率导致选择buparlisib 80 mg联合拉帕替尼1000 mg/d作为RP2D。
- 主要药物相关不良事件包括腹泻、恶心、皮疹、乏力、抑郁、焦虑和转氨酶升高。
- 未发现显著的药物-药物PK相互作用证据。
- 疾病控制率为79%[95%CI 57-92%],1例患者获得完全缓解,另有6例患者疾病稳定≥24周(临床获益率29%[95%CI 12-51%])。
关键数值与推荐
- MTD:buparlisib 80 mg/d联合拉帕替尼1250 mg/d。
- RP2D:buparlisib 80 mg联合拉帕替尼1000 mg/d。
- 疾病控制率79%[95%CI 57-92%];临床获益率29%[95%CI 12-51%]。
临床怎么用
- 在HER2阳性、曲妥珠单抗耐药的晚期乳腺癌重度经治患者中,buparlisib联合拉帕替尼的RP2D为buparlisib 80 mg联合拉帕替尼1000 mg/d。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin pathway is frequently activated in HER2-positive breast cancer and may play a major role in resistance to trastuzumab. Buparlisib is a pan-class-I PI3K inhibitor with potent and selective activity against wild-type and mutant PI3K p110 isoforms. PATIENTS AND METHODS: PIKHER2 phase IB study aimed primarily to determine a maximum tolerated dose (MTD) and propose a recommended phase II dose (RP2D) for buparlisib in combination with lapatinib in HER2-positive, trastuzumab-resistant, advanced breast cancer. Oral buparlisib (40, 60 or 80 mg) and lapatinib (750, 1000 or 1250 mg) were administered daily. A modified continuous reassessment method using an adaptive Bayesian model guided the dose escalation of both agents. Secondary end-points included antitumour activity and pharmacokinetic (PK) assessments. RESULTS: A total of 24 patients were treated across five dose levels. Dose-limiting toxicities included transaminases elevation, vomiting, stomatitis, hyperglycemia and diarrhoea. MTD was declared at buparlisib 80 mg/d + lapatinib 1250 mg/d, but toxicities and early treatment discontinuation rate beyond cycle 1 led to select buparlisib 80 mg + lapatinib 1000 mg/d as the RP2D. Main drug-related adverse events included diarrhoea, nausea, skin rash, asthenia, depression, anxiety and transaminases increase. There was no significant evidence for drug-drug PK interaction. Disease control rate was 79% [95% confidence interval [CI] 57-92%], one patient obtained a complete remission, and six additional patients experienced stable disease for ≥ 24 weeks (clinical benefit rate of 29% [95% CI 12-51%]). CONCLUSION: Combining buparlisib and lapatinib in HER2-positive trastuzumab-resistant advanced breast cancer was feasible. Preliminary evidence of antitumour activity was observed in this heavily pre-treated population. TRIAL REGISTRATION ID: NCT01589861.
引用
- Guerin M, Rezai K, Isambert N, et al. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Eur J Cancer. 2017. PMID: 28950146. doi:10.1016/j.ejca.2017.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。